$15.19
Price
$2.4B
Market Cap
—
P/E Ratio
-59.1
Forward P/E
$-0.32
EPS (TTM)
—
Dividend Yield
$218M
Cash
$79M
Total Debt
160M
Shares Out
$9.07
$20.76
52-Week Range
Institutional Ownership of ADAPTIVE BIOTECHNOLOGIES
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for ADAPTIVE BIOTECHNOLOGIES
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q3 | |||||
| BUY | +104.7% | 291.2K | $4M | $12.54 | |
| 2025-Q2 | |||||
| BUY | NEW | 142.3K | $2M | $9.09 | |
| 2020-Q4 | |||||
| SELL | -10.4% | 30.0M | $1.8B | $49.99 | |
| 2020-Q1 | |||||
| SELL | -12.8% | 33.5M | $930M | $29.39 | |
| 2019-Q2 | |||||
| BUY | NEW | 38.4M | $1.9B | $44.30 | |
Insider Trading for ADAPTIVE BIOTECHNOLOGIES
6 Months Insider Sentiment
Buy $0
Sell $7.6M
0
Buys
10
Sells
-7.6M
Net
0
Grants
Largest
$2.4M
Robins
$1.9M
Robins
$1.8M
LO
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 06, 2026 | Harlan S Robins | Chief Scientific Officer | SELL | 10.0K | $16.44 | $164K |
| Jan 05, 2026 | Chad M Robins | CEO and Chairman | SELL | 125.0K | $15.59 | $1.9M |
| Jan 02, 2026 | Francis LO | Chief People Officer | SELL | 3.1K | $16.08 | $50K |
| Jan 02, 2026 | Francis LO | Chief People Officer | EXERCISE | 3.1K | $3.99 | $12K |
| Dec 22, 2025 | Francis LO | Chief People Officer | EXERCISE | 1.1K | $7.80 | $9K |
| Dec 22, 2025 | Francis LO | Chief People Officer | EXERCISE | 2.2K | $3.99 | $9K |
| Dec 22, 2025 | Francis LO | Chief People Officer | SELL | 4.4K | $17.50 | $77K |
| Dec 15, 2025 | Francis LO | Chief People Officer | EXERCISE | 19.4K | $8.46 | $164K |
| Dec 15, 2025 | Francis LO | Chief People Officer | EXERCISE | 37.8K | $7.80 | $294K |
| Dec 15, 2025 | Francis LO | Chief People Officer | SELL | 113.9K | $15.57 | $1.8M |
| Dec 15, 2025 | Francis LO | Chief People Officer | EXERCISE | 39.8K | $3.99 | $159K |
| Dec 10, 2025 | Robert Hershberg | Director | SELL | 23.0K | $16.00 | $367K |
| Dec 04, 2025 | Sharon Benzeno | Chief Commercial Ofc Imm Med | SELL | 12.6K | $16.85 | $212K |
| Dec 04, 2025 | Harlan S Robins | Chief Scientific Officer | SELL | 10.0K | $16.61 | $166K |
| Dec 04, 2025 | Sharon Benzeno | Chief Commercial Ofc Imm Med | EXERCISE | 4.2K | $8.46 | $35K |
| Dec 04, 2025 | Sharon Benzeno | Chief Commercial Ofc Imm Med | EXERCISE | 4.3K | $12.14 | $52K |
| Dec 03, 2025 | Harlan S Robins | Chief Scientific Officer | SELL | 27.2K | $18.61 | $506K |
| Dec 01, 2025 | Chad M Robins | CEO and Chairman | SELL | 125.0K | $18.94 | $2.4M |